Navigation Links
Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/13/2008

ents, should be sufficient to fund operating expenses, scheduled debt obligations and capital equipment requirements into the first half of 2009.

Third Quarter Highlights and Recent Developments

-- Expanded Development Program for R3487/MEM 3454 with Roche. In September 2008, Memory Pharmaceuticals and Roche amended their nicotinic alpha-7 receptor agonist agreement, resulting in accelerated milestone payments to the Company. The companies agreed to expand the ongoing Phase 2 study of R3487/MEM 3454 in cognitive impairment associated with schizophrenia (CIAS) to provide for a more robust data set and increase the potential for the study to facilitate advancing the compound into a pivotal trial. The Company received $3.5 million in connection with the amendment and will receive $5.0 million upon the enrollment of the 212th patient in the trial, which is expected to occur in November 2008. An additional $8.5 million will become due 30 days following the availability of top-line data from the Phase 2 CIAS trial. In addition, Roche has agreed to fund all internal and external costs associated with expanding the trial.

-- Received Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908. In October, Memory Pharmaceuticals announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists including R3487/MEM 3454 and R4996/MEM 63908. The term of the patent extends until at least 2025, which does not reflect any potential patent term extensions.

-- Completed Phase 1 Program for R4996/MEM 63908. In September, the Company completed its Phase 1 multiple ascending dose study of R4996/MEM 63908 in healthy volunteers. The trial is the fourth and final study in the Company's Phase 1 program for the compound. The Company expects to announce top-line results from the entire Phase 1 program in the fourth quarter of 2008.

-- Presentations at Scientific Meeting
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Miniaturizing memory: Taking data storage to the molecular level
2. Memory Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
3. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Memoirs of a qubit: Hybrid memory solves key problem for quantum computing
6. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
7. Jellyfish Protein Shows Potential to Help With Memory
8. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
9. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
10. Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
11. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... “Nature has developed, very cleverly, some ... desire in optical design,” said Joseph Shaw, director of ... we explore surfaces and structures at the nanoscale, we’ll ... in San Diego in August during a conference called ... chaired by Shaw and Rongguang Liang of the University ...
(Date:9/16/2014)... From cell phones to cars and flashlights, batteries ... and technology companies constantly are seeking ways to ... first time using a water-based solution, researchers at ... and more efficient nuclear battery that could be ... energy source in automobiles and also in complicated ...
(Date:9/16/2014)... CIRTEC Medical Systems’ Board of Directors has ... CIRTEC. , “I am delighted to be joining ... Brian Highley. “The company has made great strides improving ... over the past two years. The goal now is ... expand the services Cirtec offers its medical device customers.” ...
(Date:9/16/2014)... , Sept. 16, 2014  LABSCO, the ... and products to hospitals, physician office laboratories and ... effective October 1, 2014, it will serve as ... hospital market segments and as a semi-exclusive sales ... 48 contiguous United States . ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... Merrimack Pharmaceuticals, Inc. announced today that it ... therapeutic consisting of a mixture of three human ... irinotecan, at the 14th World Conference on Lung ... in Amsterdam, The Netherlands. (Logo: ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... approved its Los Angeles cancer immunotherapy manufacturing facility, allowing ... PROVENGE ® (sipuleucel-T) across the U.S. to help ... symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.   ...
... Branch Fund: A Thisbe and Noah Scott Legacy, an ... announced its first funding award to Kevin Eggan, Ph.D., ... Harvard University.  The award will support Dr. Eggan,s ongoing ... affect it.  Dr. Eggan is a leading researcher in ...
Cached Biology Technology:Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 3FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 4The Olive Branch Fund Announces Funding Award to Harvard Researcher 2
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... The world,s leading conservation organizations have joined together to fight ... gorilla ( Gorilla beringei graueri ). Found only in ... of Congo (DRC), Grauer,s gorilla is not only the largest ... in the world. With their entire range consumed in ...
... and walked on two legs is considered to be one of ... to the far ends of the earth and the wonderful ... walk the way we walk. In the latest such search, ... have taken a closer look at bipedal kangaroos and wallabies and ...
... PA, March 13, 2013 Many Canadians are concerned ... sodium intake through a variety of measures, including lowering ... a national survey. The top barriers to limiting sodium ... processed foods and lower sodium restaurant menu options. ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3It's all in the way we move 2Canadians support interventions to reduce dietary salt 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: